Copyright
©The Author(s) 2023.
World J Clin Oncol. Aug 24, 2023; 14(8): 285-296
Published online Aug 24, 2023. doi: 10.5306/wjco.v14.i8.285
Published online Aug 24, 2023. doi: 10.5306/wjco.v14.i8.285
Table 2 Phosphoinositide 3-kinase-protein kinase-mammalian target of rapamycin-pathway inhibitors
Agent | Combination | Phase | NCT number1 |
PI3K inhibitors (p110α) isoform | |||
Alpelisib (BYL719) | Gemcitabine and abraxane | I | NCT02155088 |
Buparlisib (BKM120) | mFOLFOX6; trametinib (MEKi) | I; I | NCT01571024; NCT01155453 |
Pan-PI3K inhibitors | |||
Copanlisib(BAY 80–6946) | N/A | I | NCT00962611 |
PI3K and mTOR inhibitors | |||
Voxtalisib (SAR245409, XL765) | N/A | I | NCT00485719 |
Dactolisib(NVP-BEZ235) | MEK162 (MEKi) | I | NCT01337765 |
Gedatolisib (PF-05212384, PKI-587) | Palbociclib (CDKi) | I | NCT03065062 |
Pan-Akt inhibitors | |||
MK2206 | Monotherapy; dinaciclib (CDKi); selumitinib (MEKi) vs mFOLFOX6 | I; I; II | NCT00848718; NCT01783171; NCT01658943 |
Afuresertib (GSK2110183) | Trametinib (MEKi); N/A | I; II | NCT01476137; NCT01531894 |
Uprosertib (GSK2141795) | Trametinib (MEKi) | I | NCT01138085 |
Oleandrin (PBI-05204) | N/A | II | NCT02329717 |
Perifosine | N/A | II; II | NCT00053924; NCT00059982 |
RX-0201 | Gemcitabine | II | NCT01028495 |
Rapalogs (mTORC1 inhibitors) | |||
Sirolimus (rapamycin) | Sunitinib (RTKi); N/A; metformin; vismodegib (SMOi) | I; II; I/II; I | NCT00583063; NCT00499486; NCT02048384; NCT01537107 |
Temsirolimus (CCI-779, Torisel) | Lenalidomide; gemcitabine; nivolumab (PD-1i) | I; I; I/II | NCT01183663; NCT00593008; NCT02423954 |
Everolimus (RAD001) | Sorafenib (RTKi); trametinib (MEKi); gemcitabine; cetuximab (EGFRi) and capecitabine; N/A | I; I; I/II; I/II; II | NCT00981162; NCT00955773; NCT00560963; NCT01077986; NCT00409292 |
Ridafirolimus | Bevacizumab (VEGFRi) | I | NCT00781846 |
mTORC1/2 inhibitors | |||
Vistusertib (AZD2014) | N/A; selumitinib (MEKi); olaparib (PARPi) | I; II; II | NCT01026402; NCT02583542; NCT02576444 |
- Citation: Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol 2023; 14(8): 285-296
- URL: https://www.wjgnet.com/2218-4333/full/v14/i8/285.htm
- DOI: https://dx.doi.org/10.5306/wjco.v14.i8.285